Neurology · Alabama
Neurology studies in Alabama
56 studies have at least one recruiting site in Alabama. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
56 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Huntsville, AL + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Birmingham, AL + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Birmingham, AL + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
- Location
- Birmingham, AL + 16 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Fairhope, AL + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Huntsville, AL + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1/Phase 2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
- Location
- Birmingham, AL + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Birmingham, AL + 111 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Octapharma
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Birmingham, AL + 69 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company
- Location
- Birmingham, AL + 35 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics
- Location
- Birmingham, AL + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
AbbVie
- Location
- Birmingham, AL + 7 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
AB Science
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 18–81
- RecruitingHealthy volunteers
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Mayo Clinic
- Location
- Birmingham, AL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 4
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Duke University
- Location
- Birmingham, AL + 88 other US sites
- Eligibility basics
- Ages 75+
- RecruitingHealthy volunteers
Retraining and Control Therapy (ReACT): Sense of Control and Symptom Expectations as Targets of a Treatment for PNES
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 11–18
- RecruitingHealthy volunteers
ASSESS ALL ALS Study
St. Joseph's Hospital and Medical Center, Phoenix
- Location
- Birmingham, AL + 35 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
PREVENT ALL ALS Study
St. Joseph's Hospital and Medical Center, Phoenix
- Location
- Birmingham, AL + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 2
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 50+
- RecruitingHealthy volunteers
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Michael J. Fox Foundation for Parkinson's Research
- Location
- Birmingham, AL + 29 other US sites
- Eligibility basics
- Ages 30+
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.